Adenylate Cyclase (ACT)

Adenylate Cyclase (ACT), Recombinant from Bordetella pertussis

Catalog #



964-300 50 μg $200
964-310 200 μg $700
964-320 1 mg $2200
964-330 > 5 mg Inquire


Recombinant ACT is supplied in 0.05M MES (pH 7), 0.05M NaCl, 2M urea, 50% glycerol at a desired concentration of 0.1-0.5 mg/ml.

Adenylate cyclase (ACT) is an essential virulence factor of B. pertussis, which functions by inhibiting neutrophil defenses. The cell-invasive ACT toxin is synthesized from the cyaA gene. The gene product is a bifunctional protein of 1706 amino acids (~180 kD) exhibiting both adenylate cyclase and hemolysin activities. The capacity of ACT to penetrate into target cell membranes depends on a post-translational activation in B. pertussis by the accessory fatty-acyltransferase CyaC. The resulting modification consists of a single amide-linked palmitoylation of lysine 983 in ACT. The recombinant form of ACT from this preparation lacks the acylated modification.

The cyaA gene is PCR amplified from B. pertussis BP338 and cloned into a pET vector allowing the direct expression of non-tagged protein. The recombinant ACT protein (~180 kD) is expressed in E. coli strain BL21(DE3) and purified from inclusion bodies.
Protein Content Protein concentration was determined by Bradford assay method using bovine serum albumin as standard.

Store at -20°C. To insure uniformity, it is recommended that the ACT suspension be swirled or gently mixed prior to use.

Purity >95% by SDS-PAGE.